Shares of Vanda Pharmaceuticals VNDA increased in after-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share increased 87.50% over the past year to $0.15, which beat the estimate of $0.14.
Revenue of $67,653,000 rose by 11.03% from the same period last year, which beat the estimate of $64,000,000.
Guidance
Earnings guidance hasn't been issued by the company for now.
The upcoming fiscal year's revenue expected to be between $270,000,000 and $300,000,000.
How To Listen To The Conference Call
Date: Feb 10, 2021
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/3jdd3b89
Price Action
52-week high: $16.29
Company's 52-week low was at $7.12
Price action over last quarter: Up 40.22%
Company Description
Vanda Pharmaceuticals Inc is a biopharmaceutical company which is engaged in the development and commercialization of therapies to address high unmet medical needs and improves the lives of patients. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant (VLY-686), VTR-297, and VQW-765.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
